MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 885 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
HPK1-IN-14
CAS:<p>HPK1-IN-14 is a potent inhibitor of HPK1. HPK1-IN-14 has potential for the study of HPK1-related diseases.</p>Formula:C24H23FN6O2Color and Shape:SolidMolecular weight:446.48pan-Raf/RTK inhibitor 1
CAS:<p>Pan-Raf/RTK inhibitor 1 (compound I-16) is a potent pan-Raf inhibitor with IC50 values of 3.49 nM (BRafV600E), 8.86 nM (ARaf), 5.78 nM (BRafWT), and 1.65 nM (CRaf). It exhibits antiproliferative activity against various cancer cell lines and can be utilized in cancer research.</p>Formula:C29H28F3N7O3Color and Shape:SolidMolecular weight:579.573SOS1-IN-10
<p>SOS1-IN-10 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 13 nM).</p>Formula:C22H19F5N4OColor and Shape:SolidMolecular weight:450.4KRAS G12D inhibitor 1
CAS:<p>KRAS G12D inhibitor 1 (example 243) is an inhibitor of KRAS G12D with an IC 50 of 0.8 nM for KRAS G12D-mediated ERK phosphorylation [1].</p>Formula:C33H32F2N6O2Color and Shape:SolidMolecular weight:582.64p38-α MAPK-IN-5
CAS:<p>p38-α MAPK-IN-5: potent p38α inhibitor, IC50s: 0.1 nM (α), 0.2 nM (β), 944 nM (γ), 4100 nM (δ); anti-inflammatory, promising for asthma/COPD research.</p>Formula:C37H49N11O2Color and Shape:SolidMolecular weight:679.86KU004
CAS:<p>KU004, a potent dual EGFR/HER2 inhibitor, exhibits anticancer properties. It inhibits the proliferation of human breast cancer SKBR3 cells by inducing G1 phase arrest. KU004 blocks the activation of HER2, EGFR, and the downstream Akt and Erk pathways, primarily inducing apoptosis (Apoptosis) through the extrinsic pathway. Additionally, KU004 is a novel quinazoline derivative.</p>Formula:C29H27ClFN4O2PColor and Shape:SolidMolecular weight:548.98KRAS inhibitor-27
CAS:<p>KRAS inhibitor-27 (Compound 15h) is a KRAS inhibitor that effectively targets KRAS G12D/G12V mutated cells (AsPC-1 and SW620) and wild-type KRAS cells (HT-29), with IC50 values of 378 nM, 0.6 nM, and 3230 nM, respectively. It reduces ERK phosphorylation, with IC50 values of 0.6 nM and 1 nM in AsPC-1 and SW620 cells, respectively, and decreases DUSP4 expression, thereby inhibiting the MAPK signaling pathway.</p>Formula:C31H28ClF3N6O3SColor and Shape:SolidMolecular weight:657.106p38α-MK2-IN-1
CAS:<p>p38α-MK2-IN-1 (Compound 36) is an inhibitor of the p38α-MK2 complex, with an IC50 of 5 nM. This compound exhibits significant anti-inflammatory properties and has the ability to aid in joint repair.</p>Formula:C27H26F3N5O3Color and Shape:SolidMolecular weight:525.522KRAS inhibitor-8
CAS:<p>KRAS inhibitor-8 is a potent KRAS G12C inhibitor.</p>Formula:C26H24ClF4N5O3Purity:98%Color and Shape:SolidMolecular weight:565.95PF-03715455
CAS:<p>PF-03715455 is a potent p38 MAPK inhibitor, reducing TNFα in blood (IC50=1.7 nM) with selectivity for p38α, and may treat COPD.</p>Formula:C35H34ClN7O3S2Purity:98%Color and Shape:SolidMolecular weight:700.27RGT-018
CAS:<p>RGT-018 is a potent oral SOS1 inhibitor with antitumor properties. It exerts its anticancer activity by inhibiting KRAS activation, thereby hindering cancer cell proliferation.</p>Formula:C27H24F3N7O2Color and Shape:SolidMolecular weight:535.52PS-166276
CAS:<p>PS-166276 is a potent p38 inhibitor with low cytotoxicity. It exhibits an IC50 value of 28 nM against p38 kinase and an IC50 of 170 nM in the THP-1 TNFα assay.</p>Formula:C20H30N8OColor and Shape:SolidMolecular weight:398.51Luvometinib
CAS:<p>Luvometinib is an inhibitor of the mitogen-activated protein kinase (MEK) with antitumor activity.</p>Formula:C26H22F2IN5O4SColor and Shape:SolidMolecular weight:665.45KRAS inhibitor-31
CAS:<p>KRAS inhibitor-31 (compound 33), a potent agent targeting KRAS, exhibits K D (SPR) values of 0.019 nM for KRas G12D, 0.019 nM for KRas G12C, and 0.096 nM for KRas G12V, illustrating its efficacy across these variants.</p>Formula:C33H30F3N5O4Color and Shape:SolidMolecular weight:617.62KRas G12C inhibitor 2
CAS:<p>KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.</p>Formula:C32H37N7O3Purity:98%Color and Shape:SolidMolecular weight:567.68FMK-MEA
CAS:<p>FMK-MEA is a potent and selective p90 Ribosomal S6 Kinase (RSK) inhibitor.</p>Formula:C21H26FN5O2Purity:98%Color and Shape:SolidMolecular weight:399.46KRAS G12D inhibitor 26
CAS:<p>KRAS G12D inhibitor 26 (Compound 64B) is an inhibitor of KRAS G12D with an IC50 ≤ 100 nM.</p>Formula:C35H44ClFN8O2Purity:99.93%Color and Shape:SolidMolecular weight:663.23SR-302
CAS:<p>SR-302 is a potent and selective inhibitor of DDR/p38, with IC50 values of 0.125 μM for p38α, 0.023 μM for DDR1, and 0.018 μM for DDR2. It is utilized in research related to fibrotic diseases, such as kidney and lung fibrosis, atherosclerosis, and various types of cancer.</p>Formula:C32H42N6O5SColor and Shape:SolidMolecular weight:622.778(R)-STU104-d6
CAS:<p>(R)-STU104-d6 is a deuterium-labeled variant of (R)-STU104. This compound acts as a potent and orally active inhibitor of the interaction between TAK1 and MKK3 proteins, exhibiting IC50 values of 0.58 μM for TNF-α and 4.0 μM for MKK3 phosphorylation. By binding to MKK3, (R)-STU104 hinders TAK1's ability to phosphorylate MKK3, thereby disrupting the TAK1/MKK3/p38/MnK1/MK2/elF4E signaling pathway. It is utilized in research related to ulcerative colitis.</p>Formula:C18H182D6O4Color and Shape:SolidMolecular weight:304.37MRTX-EX185
<p>MRTX-EX185 inhibits GDP-KRAS/G12D; IC50=90 nM on G12D. It also binds GDP-HRAS.</p>Formula:C33H33FN6O2Color and Shape:SolidMolecular weight:564.65
